Invitrx Therapeutics

Invitrx Therapeutics is a biotechnology company founded in July 2003 by Habib Torfi, specializing in regenerative cell therapies. The company focuses on culture and engineering of adult stem cells, utilizing the technology in aesthetics, wound closure, plastic and reconstructive surgery. Invitrx's research and clinical trials have been initially aimed at treating patients with burns, diabetic ulcers, ocular surface disorders, and other ophthalmic conditions. The company has developed methods to harvest and concentrate stem cells, leading to the development of ReLuma, a line of cosmetic products designed to rejuvenate and reactivate dormant cells, reduce signs of aging, and promote youthful, even-toned skin. These products utilize adult stem cell conditioned media containing cytokines and growth factors, demonstrating remarkable results in anti-aging by reducing blemishes, fine lines, and wrinkles. Invitrx stands out as a pioneer in utilizing adult stem cell technology for a wide range of applications. With its innovative products bridging the gap between regenerative medicine and aesthetics, the company presents a compelling opportunity for venture capital investment, especially considering the potential for further product development and market expansion.